Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.
Remacha
Angel F
AF
Arrizabalaga
Beatriz
B
Bueno
Javier
J
Muñoz
Juan
J
Bargay
Joan
J
Pedro
Carme
C
D004351:Drug Resistance; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011994:Recombinant Proteins
D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D009173:Mycophenolic Acid